Dr Madhumita Sadhukhan, MD | |
802 New Holland Ave Ste 200, Lancaster, PA 17602-2288 | |
(717) 299-6371 | |
(717) 945-1587 |
Full Name | Dr Madhumita Sadhukhan |
---|---|
Gender | Female |
Speciality | Family Practice |
Experience | 27 Years |
Location | 802 New Holland Ave Ste 200, Lancaster, Pennsylvania |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1073563292 | NPI | - | NPPES |
158841 | Other | PA | MEDICARE GROUP NUMBER |
0017987600001 | Medicaid | PA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | MD071289L (Pennsylvania) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Lancaster General Hospital | Lancaster, PA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Welsh Mountain Health Centers | 8123914322 | 12 |
News Archive
The widespread roll-out of mobile and digital health technology could have already saved the NHS over £1 billion in the last 5 years by enabling patients to leave hospital sooner, according to a new report by the Institution of Mechanical Engineers.
Arrowhead Research Corporation announced today that its portfolio company, Leonardo Biosystems, has received a $2.5 million grant from the Texas Emerging Technology Fund, a state fund established to accelerate commercialization of new technologies. Leonardo Biosystems, co-founded by prominent nanoscientist Dr. Mauro Ferrari, professor at the University of Texas, and Arrowhead's, CEO Dr. Christopher Anzalone, is engineering a multi-stage drug delivery platform to improve the effectiveness of drug therapy, particularly for cancer.
Scientists at the University of Leicester are investigating how the stuff of stink bombs and flatulence could play a critical role in the human reproductive system.
Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that pretargeted therapy with TF2, a bispecific antibody against carcinoembryonic antigen (CEA) and a small peptide, delayed tumor growth and prolonged survival in an animal model of human colonic cancer.
A drug used in some countries to treat the symptoms of Huntington's disease prevents death of brain cells in mice genetically engineered to mimic the hereditary condition, UT Southwestern Medical Center researchers have found.
› Verified 9 days ago
Entity Name | Welsh Mountain Health Centers |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1134458789 PECOS PAC ID: 8123914322 Enrollment ID: O20040608000860 |
News Archive
The widespread roll-out of mobile and digital health technology could have already saved the NHS over £1 billion in the last 5 years by enabling patients to leave hospital sooner, according to a new report by the Institution of Mechanical Engineers.
Arrowhead Research Corporation announced today that its portfolio company, Leonardo Biosystems, has received a $2.5 million grant from the Texas Emerging Technology Fund, a state fund established to accelerate commercialization of new technologies. Leonardo Biosystems, co-founded by prominent nanoscientist Dr. Mauro Ferrari, professor at the University of Texas, and Arrowhead's, CEO Dr. Christopher Anzalone, is engineering a multi-stage drug delivery platform to improve the effectiveness of drug therapy, particularly for cancer.
Scientists at the University of Leicester are investigating how the stuff of stink bombs and flatulence could play a critical role in the human reproductive system.
Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that pretargeted therapy with TF2, a bispecific antibody against carcinoembryonic antigen (CEA) and a small peptide, delayed tumor growth and prolonged survival in an animal model of human colonic cancer.
A drug used in some countries to treat the symptoms of Huntington's disease prevents death of brain cells in mice genetically engineered to mimic the hereditary condition, UT Southwestern Medical Center researchers have found.
› Verified 9 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Madhumita Sadhukhan, MD 304 N Water St, Lancaster, PA 17603-3374 Ph: (717) 735-6808 | Dr Madhumita Sadhukhan, MD 802 New Holland Ave Ste 200, Lancaster, PA 17602-2288 Ph: (717) 299-6371 |
News Archive
The widespread roll-out of mobile and digital health technology could have already saved the NHS over £1 billion in the last 5 years by enabling patients to leave hospital sooner, according to a new report by the Institution of Mechanical Engineers.
Arrowhead Research Corporation announced today that its portfolio company, Leonardo Biosystems, has received a $2.5 million grant from the Texas Emerging Technology Fund, a state fund established to accelerate commercialization of new technologies. Leonardo Biosystems, co-founded by prominent nanoscientist Dr. Mauro Ferrari, professor at the University of Texas, and Arrowhead's, CEO Dr. Christopher Anzalone, is engineering a multi-stage drug delivery platform to improve the effectiveness of drug therapy, particularly for cancer.
Scientists at the University of Leicester are investigating how the stuff of stink bombs and flatulence could play a critical role in the human reproductive system.
Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that pretargeted therapy with TF2, a bispecific antibody against carcinoembryonic antigen (CEA) and a small peptide, delayed tumor growth and prolonged survival in an animal model of human colonic cancer.
A drug used in some countries to treat the symptoms of Huntington's disease prevents death of brain cells in mice genetically engineered to mimic the hereditary condition, UT Southwestern Medical Center researchers have found.
› Verified 9 days ago
Jon David Lepley, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 540 Duke St, Lancaster, PA 17602 Phone: 717-544-4950 | |
Dr. Lindsi Anne Dearment, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1871 Santa Barbara Dr Ste 1, Lancaster, PA 17601 Phone: 717-560-1970 Fax: 717-560-2278 | |
Emily Kirchner, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 555 N Duke St, Lancaster, PA 17602 Phone: 717-544-4940 | |
Dr. John T Cotter Jr., MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2207 Oregon Pike Ste 202, Lancaster, PA 17601 Phone: 717-560-6470 Fax: 717-560-6472 | |
Dr. Spencer D Phillips, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2113 Manor Ridge Dr, Lancaster, PA 17603 Phone: 717-517-7841 Fax: 717-517-7853 | |
Danielle J Miller, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 3045 Marietta Ave, Lancaster, PA 17601 Phone: 717-898-2900 | |
Dr. Christine Janouschek, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 210 S Prince St, Lancaster, PA 17603 Phone: 717-393-7709 |